Centaurus Financial’s Cytokinetics CYTK Stock Holding History

Centaurus Financial’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-10	Closed	–	–	848
2018 Q2	$0	Buy	+10	New	+$83	﹤0.01%	2254

Other funds holding CYTK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LPU

Lansdowne Partners (UK) London, United Kingdom $1.87B AUM 61.55% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Centaurus Financial's CYTK Position: Q3 2018 in Review

Centaurus Financial sold out of Cytokinetics (CYTK) in Q3 2018, closing a stake of 10 shares.

Centaurus Financial first reported a position in CYTK in Q2 2018 and held it in 1 quarter. The position peaked at $0 in Q2 2018. 122 funds tracked by Wall St. Rank hold CYTK as of Q3 2018.

Centaurus Financial reported no remaining Cytokinetics position as of Q3 2018 after selling out during the quarter.
Centaurus Financial sold 10 Cytokinetics shares in Q3 2018.
Centaurus Financial first reported a position in Cytokinetics in Q2 2018 and held it in 1 quarter.
Centaurus Financial's Cytokinetics position peaked at $0 in Q2 2018.
122 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2018.

Based on Centaurus Financial's 13F filing for Q3 2018, filed 5 Nov 2018.